Spotlight on Internal Medicine
Immune-Mediated Inflammatory Disease Curbside Consults: Updates in Non-TNF Biologic Options for Patients With IBD
StartActivity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to examine the latest clinical safety and efficacy of available and emerging non-tumor necrosis factor biologics for the management of patients with inflammatory bowel disease.
Activity Description
In this Curbside Consult video, Drs. Miguel Regueiro and Benjamin Cohen discuss the clinical evidence to support emerging treatment options for a patient with biologic-naïve Crohn’s disease.
Activity Chair

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty

Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Sublimity Therapeutics, Target PharmaSolutions
Contracted Research: AbbVie

Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
Disclosures:
Royalties: Wolters Kluwer Health/UpToDate
Consulting Fee: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target PharmaSolutions, UCB
Contracted Research: AbbVie, Janssen, Pfizer, Takeda
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to examine the latest clinical safety and efficacy of available and emerging non-tumor necrosis factor biologics for the management of patients with inflammatory bowel disease.
Activity Description
In this Curbside Consult video, Drs. Miguel Regueiro and Benjamin Cohen discuss the clinical evidence to support emerging treatment options for a patient with biologic-naïve Crohn’s disease.
Activity Chair

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty

Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Sublimity Therapeutics, Target PharmaSolutions
Contracted Research: AbbVie

Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
Disclosures:
Royalties: Wolters Kluwer Health/UpToDate
Consulting Fee: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target PharmaSolutions, UCB
Contracted Research: AbbVie, Janssen, Pfizer, Takeda
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Internal Medicine Presentations

Recent Advances in the Management of Psoriasis
StartActivity Details
AANP Contact Hours
AAPA Category 1 CME credit
Expires: December 30, 2021
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Review the pathophysiology and comorbidities associated with psoriasis.
- Apply current guideline-directed recommendations to the management of patients with psoriasis.
- Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
- Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.
Activity Description
Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.
Activity Co-Chairs

Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB

Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI
Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for
1.0 contact hour(s) of continuing education (which includes 0.67 hours
of pharmacology) by the American Association of Nurse Practitioners. Activity
ID 20124656. This activity was planned in accordance with AANP Accreditation
Standards and Policies.
This activity has been
reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.
This activity is designated for 1 AAPA Category 1 CME credits.
Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit
commensurate with the extent of their participation. AAPA reference number:
CME-201757.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.
MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an
Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the
Merit-based Incentive Payment Program (MIPS). Participants who successfully
complete the activity and its performance assessment will receive printable
documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
AANP Contact Hours
AAPA Category 1 CME credit
Expires: December 30, 2021
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Review the pathophysiology and comorbidities associated with psoriasis.
- Apply current guideline-directed recommendations to the management of patients with psoriasis.
- Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
- Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.
Activity Description
Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.
Activity Co-Chairs

Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB

Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI
Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for
1.0 contact hour(s) of continuing education (which includes 0.67 hours
of pharmacology) by the American Association of Nurse Practitioners. Activity
ID 20124656. This activity was planned in accordance with AANP Accreditation
Standards and Policies.
This activity has been
reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.
This activity is designated for 1 AAPA Category 1 CME credits.
Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit
commensurate with the extent of their participation. AAPA reference number:
CME-201757.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.
MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an
Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the
Merit-based Incentive Payment Program (MIPS). Participants who successfully
complete the activity and its performance assessment will receive printable
documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com

Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum℠
StartActivity Details
Expires: December 29, 2021
Provided By
This activity is jointly provided by AKH Inc., Advancing Knowledge in
Healthcare and RMEI Medical Education, LLC.
Target Audience
This activity is designed for infectious disease, critical care, and primary care clinicians.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
- Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
- Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections
Activity Description
During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.
Statement of Educational Need
Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.
Faculty
Chair
Professor
Department of Pharmacy
Albany College of Pharmacy and Health Services
Albany, NY

Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ

Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada
Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following
financial relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the content of
this activity:
Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta,
Shionogi Inc. (Speakers Bureau)
Joseph Reilly, BS, PharmD, BCGP, has affiliations
with:
Cumberland, Melinta (Speakers Bureau)
Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has
affiliations with:
Sunovion (Speakers Bureau)
The planners and managers reported the
following financial relationships or relationships to products or devices
they or their spouse/life partner have with commercial interests related to
the content of this activity:
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation,
Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of
Operations, has no financial relationships to
disclose.
RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical
Director, has no financial relationships to
disclose.
Sharon Powell, Editor, has no financial
relationships to disclose.
The RMEI Medical Education planners and
managers have nothing to disclose.
Accreditation Statement
Physicians
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of AKH
Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide
continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity
for a maximum of 1.0 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from
organizations accredited by ACCME.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.0 medical knowledge MOC points and 0
patient safety credit in the American Board of Internal Medicine’s
(ABIM) Maintenance of Certification (MOC) program. It is the CME activity
provider’s responsibility to submit participant completion information
to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Melinta Therapeutics, Inc.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Contact Information for Questions About the Activity
Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.
Activity Details
Expires: December 29, 2021
Provided By
This activity is jointly provided by AKH Inc., Advancing Knowledge in
Healthcare and RMEI Medical Education, LLC.
Target Audience
This activity is designed for infectious disease, critical care, and primary care clinicians.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
- Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
- Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections
Activity Description
During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.
Statement of Educational Need
Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.
Faculty
Chair
Professor
Department of Pharmacy
Albany College of Pharmacy and Health Services
Albany, NY

Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ

Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada
Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following
financial relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the content of
this activity:
Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta,
Shionogi Inc. (Speakers Bureau)
Joseph Reilly, BS, PharmD, BCGP, has affiliations
with:
Cumberland, Melinta (Speakers Bureau)
Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has
affiliations with:
Sunovion (Speakers Bureau)
The planners and managers reported the
following financial relationships or relationships to products or devices
they or their spouse/life partner have with commercial interests related to
the content of this activity:
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation,
Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of
Operations, has no financial relationships to
disclose.
RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical
Director, has no financial relationships to
disclose.
Sharon Powell, Editor, has no financial
relationships to disclose.
The RMEI Medical Education planners and
managers have nothing to disclose.
Accreditation Statement
Physicians
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of AKH
Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide
continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity
for a maximum of 1.0 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from
organizations accredited by ACCME.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.0 medical knowledge MOC points and 0
patient safety credit in the American Board of Internal Medicine’s
(ABIM) Maintenance of Certification (MOC) program. It is the CME activity
provider’s responsibility to submit participant completion information
to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Melinta Therapeutics, Inc.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Contact Information for Questions About the Activity
Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

New Horizons in Migraine Prevention: Pathways to Personalized Care with CGRPs—the Year in Review
StartActivity Details
Expires: November 21, 2021
Accredited By
Target Audience
This activity is intended for neurologists, headache specialists, pain specialists, NPs, PAs, and other HCPs who treat patients with migraine disorder.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Develop effective strategies for incorporating CGRP mABs into daily clinical practice
- Formulate comprehensive management plans for migraine patients on preventative treatment
- Review current treatment guidelines and patient eligibility for use of CGRP mABs
Activity Description
Join an expert faculty panel as they discuss incorporating anti-CGRP monoclonal antibodies into daily clinical practice for migraine prevention. This video-based session will integrate didactic presentation, a case-based panel discussion, and expert review of clinical evidence, guideline recommendations, special considerations, and real-world use.
Statement of Educational Need
Migraines represent a common, debilitating disorder that continues to be both undertreated and underdiagnosed. Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are an emerging preventative migraine therapy class that offer benefits over traditional systemic prophylaxis. This activity will review best practices for incorporating CGRP mAbs into daily clinical practice.
Chair

Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC
Faculty

Professor of Neurology, Department of Neurology
Mayo Clinic College of Medicine
Consultant in Neurology and Program Director, Mayo Clinic Neurology Residency Program
Director, Headache, Sports Neurology, and Concussion Programs
Mayo Clinic
Scottsdale, AZ

Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Jessica Ailani, MD, FAHS, FAAN
Consulting Agreements: Alder, Amgen, Allergan, Biohaven, Eli Lilly and
Company, Impel, Neurodiem, Revance, Satsuma, Theranica, Teva, Zosano
Speakers’ Bureau: Allergan, Amgen, Biohaven, Eli Lilly and Company,
Teva
David W. Dodick, MD
Board of Directors: Epien Medical
Consulting Agreements: Allergan, Amgen, Biohaven Pharmaceuticals, Cerecin,
Clexio Biosciences Ltd., Ctrl M Health, Eli Lilly and Company, eNeura,
Equinox Pharma, Linpharma, Lundbeck, Novartis, Impel Neuro Pharma, Nocira,
Pieris Pharmaceuticals, Inc., Promius Pharma, LLC, Revance, Satsuma
Pharmaceuticals, Theranica, WL Gore, XoC Pharmaceuticals, Zosano Pharma,
Upjohn (Division of Pfizer)
Patent 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic
Migraine Prophylaxis
Stock Options: Ctrl M Health, Epien Medical, Healint, Nocira, Theranica
Lawrence C. Newman, MD, FAHS, FAAN
Advisory Board: Allergan, Amgen, Eli Lilly and Company, Supernus,
Theranica
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
Instructions for Receiving Credit
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Lundbeck.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
Activity Details
Expires: November 21, 2021
Accredited By
Target Audience
This activity is intended for neurologists, headache specialists, pain specialists, NPs, PAs, and other HCPs who treat patients with migraine disorder.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Develop effective strategies for incorporating CGRP mABs into daily clinical practice
- Formulate comprehensive management plans for migraine patients on preventative treatment
- Review current treatment guidelines and patient eligibility for use of CGRP mABs
Activity Description
Join an expert faculty panel as they discuss incorporating anti-CGRP monoclonal antibodies into daily clinical practice for migraine prevention. This video-based session will integrate didactic presentation, a case-based panel discussion, and expert review of clinical evidence, guideline recommendations, special considerations, and real-world use.
Statement of Educational Need
Migraines represent a common, debilitating disorder that continues to be both undertreated and underdiagnosed. Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are an emerging preventative migraine therapy class that offer benefits over traditional systemic prophylaxis. This activity will review best practices for incorporating CGRP mAbs into daily clinical practice.
Chair

Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC
Faculty

Professor of Neurology, Department of Neurology
Mayo Clinic College of Medicine
Consultant in Neurology and Program Director, Mayo Clinic Neurology Residency Program
Director, Headache, Sports Neurology, and Concussion Programs
Mayo Clinic
Scottsdale, AZ

Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Jessica Ailani, MD, FAHS, FAAN
Consulting Agreements: Alder, Amgen, Allergan, Biohaven, Eli Lilly and
Company, Impel, Neurodiem, Revance, Satsuma, Theranica, Teva, Zosano
Speakers’ Bureau: Allergan, Amgen, Biohaven, Eli Lilly and Company,
Teva
David W. Dodick, MD
Board of Directors: Epien Medical
Consulting Agreements: Allergan, Amgen, Biohaven Pharmaceuticals, Cerecin,
Clexio Biosciences Ltd., Ctrl M Health, Eli Lilly and Company, eNeura,
Equinox Pharma, Linpharma, Lundbeck, Novartis, Impel Neuro Pharma, Nocira,
Pieris Pharmaceuticals, Inc., Promius Pharma, LLC, Revance, Satsuma
Pharmaceuticals, Theranica, WL Gore, XoC Pharmaceuticals, Zosano Pharma,
Upjohn (Division of Pfizer)
Patent 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic
Migraine Prophylaxis
Stock Options: Ctrl M Health, Epien Medical, Healint, Nocira, Theranica
Lawrence C. Newman, MD, FAHS, FAAN
Advisory Board: Allergan, Amgen, Eli Lilly and Company, Supernus,
Theranica
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
Instructions for Receiving Credit
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Lundbeck.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma
StartActivity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis
StartActivity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize adverse events related to biologics used to treat atopic diseases
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize adverse events related to biologics used to treat atopic diseases
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy
StartActivity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Redefining the Diagnosis and Therapy of COPD: Lessons from COPDGene, GOLD Reports, and Precision Medicine
StartActivity Details
Expires: December 21, 2021
Accredited By
Target Audience
This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with COPD.
Learning Objectives
- Identify clinical, functional, and radiological characteristics that can facilitate earlier COPD diagnosis and recognition of those who can benefit from available therapies
- Recognize the importance of smoking cessation, early treatment, and other prevention approaches in alleviating the burden of COPD
- Apply precision medicine-based approaches and current GOLD strategy to improve individualized treatment of COPD
- Describe the ongoing evolution of COPD diagnosis and its management in the era of COVID-19
Statement of Educational Need
Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, clinical practice has consistently underdiagnosed and undertreated this condition. As a result, patients with COPD continue to be associated with a poor quality of life, and there has remained an unmet need to improve its continuum of care. Recent data have shown that, using new criteria and methodologies, the definition of COPD can be broadened to include patients who would have been excluded from a previously characterized definite diagnosis. In addition, earlier treatment of such patients with pharmacologic, non-pharmacologic, and preventive strategies would be of benefit in reducing the burden of symptoms. Furthermore, implementation of updated guidelines and novel precision medicine-based approaches to individualize management of diverse patients with COPD will also be critical to improving outcomes. This continuing education program will clarify the clinical implications of new perspectives in the diagnosis, treatment, and management of this complicated disease.
Faculty

Professor of Medicine
Chair, Department of Thoracic Medicine & Surgery
Lewis Katz School of Medicine
Temple University Co-Director, Center for Inflammation and Lung Research
Medical Director, Pulmonary Service Line
Temple University Hospital
Philadelphia, Pennsylvania

Chief, Division of Pulmonary and Critical Care Medicine
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York

President and Chief Scientific Officer
COPD Foundation
Washington, District of Columbia
President, TALSi Translational Medicine Consulting, LLC
Greater Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Gerard Criner, MD, FACP, FACCP
Consulting Fees: Amgen, AstraZeneca, Boehringer
Ingelheim, Broncus Medical, CSA Medical, Eolo Medical,
Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck,
Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis,
Olympus, PulmonX, Philips Respironics, Respivant Sciences, The
Implementation Group, Verona Pharma
Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL
Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron
Contracted Research: Afferent/Merck, Bayer, Biogen,
Gilead, GlaxoSmithKline, Respivant
Science, ProMedior/Roche, Veracyte
Ruth Tal-Singer, PhD
Former employee and current shareholder of GSK and reports personal fees from
Vocalis Health, ImmunoMet, and Ena Respiratory.
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The Integrity CE planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of December 21, 2020 through December 21, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from AstraZeneca.
Activity Details
Expires: December 21, 2021
Accredited By
Target Audience
This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with COPD.
Learning Objectives
- Identify clinical, functional, and radiological characteristics that can facilitate earlier COPD diagnosis and recognition of those who can benefit from available therapies
- Recognize the importance of smoking cessation, early treatment, and other prevention approaches in alleviating the burden of COPD
- Apply precision medicine-based approaches and current GOLD strategy to improve individualized treatment of COPD
- Describe the ongoing evolution of COPD diagnosis and its management in the era of COVID-19
Statement of Educational Need
Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, clinical practice has consistently underdiagnosed and undertreated this condition. As a result, patients with COPD continue to be associated with a poor quality of life, and there has remained an unmet need to improve its continuum of care. Recent data have shown that, using new criteria and methodologies, the definition of COPD can be broadened to include patients who would have been excluded from a previously characterized definite diagnosis. In addition, earlier treatment of such patients with pharmacologic, non-pharmacologic, and preventive strategies would be of benefit in reducing the burden of symptoms. Furthermore, implementation of updated guidelines and novel precision medicine-based approaches to individualize management of diverse patients with COPD will also be critical to improving outcomes. This continuing education program will clarify the clinical implications of new perspectives in the diagnosis, treatment, and management of this complicated disease.
Faculty

Professor of Medicine
Chair, Department of Thoracic Medicine & Surgery
Lewis Katz School of Medicine
Temple University Co-Director, Center for Inflammation and Lung Research
Medical Director, Pulmonary Service Line
Temple University Hospital
Philadelphia, Pennsylvania

Chief, Division of Pulmonary and Critical Care Medicine
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York

President and Chief Scientific Officer
COPD Foundation
Washington, District of Columbia
President, TALSi Translational Medicine Consulting, LLC
Greater Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Gerard Criner, MD, FACP, FACCP
Consulting Fees: Amgen, AstraZeneca, Boehringer
Ingelheim, Broncus Medical, CSA Medical, Eolo Medical,
Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck,
Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis,
Olympus, PulmonX, Philips Respironics, Respivant Sciences, The
Implementation Group, Verona Pharma
Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL
Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron
Contracted Research: Afferent/Merck, Bayer, Biogen,
Gilead, GlaxoSmithKline, Respivant
Science, ProMedior/Roche, Veracyte
Ruth Tal-Singer, PhD
Former employee and current shareholder of GSK and reports personal fees from
Vocalis Health, ImmunoMet, and Ena Respiratory.
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The Integrity CE planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of December 21, 2020 through December 21, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from AstraZeneca.

Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP)
StartActivity Details
Expires: December 13, 2021
Accredited By

Target Audience
This activity is intended for hematologists, emergency medicine physicians, critical care physicians, and primary care providers.
Learning Objectives
Upon completion of this course, the participants should be able to:
- Differentiate acquired TTP from hereditary TTP
- Recognize cardinal features in the presentation of TTP
- Diagnose TTP accurately using recommended tests
- Distinguish between TTP and other disorders in a differential diagnosis
Statement of Educational Need
Given the recent updates in research, progress in diagnosis and treatment, and the rarity of TTP and its associated 90%+ mortality rate if untreated, it is imperative that physicians become conversant with the disorder and the new information associated with its recognition, diagnosis, and treatment.
Faculty

Head, Division of Transfusion Medicine
St. Michael’s Hospital
University of Toronto
Toronto, Canada
Katerina Pavenski, MD, FRCPC, has served as a consultant for Alexion, Sanofi, and Takeda. She has received contract research support from Sanofi.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, TFF and the ISTH require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and the ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and the ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physicians
TFF designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Nurses
Nurses certified by the American Nurses Credentialing Center (ANCC) may
utilize activities that are certified by ACCME-accredited providers toward
their requirement for certification renewal by the ANCC. A certificate of
attendance will be provided by TFF, an ACCME-accredited provider.
Instructions for Receiving Credit
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by educational grants from Shire and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF and the ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected for their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, the ISTH, and the commercial supporter(s) assume no liability for the information herein.
TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational. This includes any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
Expires: December 13, 2021
Accredited By

Target Audience
This activity is intended for hematologists, emergency medicine physicians, critical care physicians, and primary care providers.
Learning Objectives
Upon completion of this course, the participants should be able to:
- Differentiate acquired TTP from hereditary TTP
- Recognize cardinal features in the presentation of TTP
- Diagnose TTP accurately using recommended tests
- Distinguish between TTP and other disorders in a differential diagnosis
Statement of Educational Need
Given the recent updates in research, progress in diagnosis and treatment, and the rarity of TTP and its associated 90%+ mortality rate if untreated, it is imperative that physicians become conversant with the disorder and the new information associated with its recognition, diagnosis, and treatment.
Faculty

Head, Division of Transfusion Medicine
St. Michael’s Hospital
University of Toronto
Toronto, Canada
Katerina Pavenski, MD, FRCPC, has served as a consultant for Alexion, Sanofi, and Takeda. She has received contract research support from Sanofi.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, TFF and the ISTH require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and the ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and the ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physicians
TFF designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Nurses
Nurses certified by the American Nurses Credentialing Center (ANCC) may
utilize activities that are certified by ACCME-accredited providers toward
their requirement for certification renewal by the ANCC. A certificate of
attendance will be provided by TFF, an ACCME-accredited provider.
Instructions for Receiving Credit
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by educational grants from Shire and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF and the ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected for their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, the ISTH, and the commercial supporter(s) assume no liability for the information herein.
TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational. This includes any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

What Have We Learned? The Neverending Story of COVID-19 and ILD
StartActivity Details
Expires: December 10, 2021
Accredited By
Target Audience
This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
- Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
- Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS
Activity Description
What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!
Statement of Educational Need
Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.
Faculty

Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.
Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.
As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.
As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.
Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Activity Details
Expires: December 10, 2021
Accredited By
Target Audience
This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
- Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
- Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS
Activity Description
What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!
Statement of Educational Need
Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.
Faculty

Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.
Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.
As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.
As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.
Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org

Managing Influenza in At-Risk Patients to Reduce Infection
StartActivity Details
ABIM MOC
Expires: December 8, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is pulmonologists and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Implement diagnostic procedures that improve the early detection of influenza in high-risk patients.
- Differentiate antiviral treatments in terms of efficacy, safety, and their ability to reduce infection and complications in high-risk patients.
- Incorporate the most appropriate therapeutic regimen in patients with suspected influenza, and who are at high risk for complications.
Activity Description
The majority of influenza hospitalizations and deaths occur in patients at high risk for developing complications, including immunocompromised individuals and those with preexisting respiratory conditions. Prevention of infection in patients at high risk for influenza complications is especially critical given the ongoing COVID-19 pandemic. This CME program will deliver the latest data and recommendations regarding timely diagnosis and treatment of influenza so that clinicians are well-equipped to compare the efficacy and safety of available antiviral therapies for influenza prophylaxis and treatment. Using case examples, experts will discuss strategies for incorporating the most appropriate therapeutic regimen to reduce morbidity and mortality in patients who are at high risk for influenza-related complications.
Activity Chair

Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Institute for Global Health and Infectious Diseases
The University of North Carolina School of Medicine
Chapel Hill, NC
Disclosure:
Adjudication Committee: Janssen, Syneos
Faculty

Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Chicago, IL
Disclosure:
Royalty: UpToDate
Consulting Fee: AlloVir, Celltrion, Genentech/Roche, Janssen, Shionogi, Viracor Eurofins
Contracted Research: AiCuris, Genentech/Roche, Janssen, Shire

George and Esther Gross Presidential Professor
Chief, Division of Pediatric Infectious Diseases
University of Utah
Director, Hospital Epidemiology Program
Primary Children's Hospital
Salt Lake City, UT
Disclosure:
Royalty: Antimicrobial Therapy, Inc.
Consulting Fee: Genentech, Merck, Seqirus
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.75 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC
Expires: December 8, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is pulmonologists and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Implement diagnostic procedures that improve the early detection of influenza in high-risk patients.
- Differentiate antiviral treatments in terms of efficacy, safety, and their ability to reduce infection and complications in high-risk patients.
- Incorporate the most appropriate therapeutic regimen in patients with suspected influenza, and who are at high risk for complications.
Activity Description
The majority of influenza hospitalizations and deaths occur in patients at high risk for developing complications, including immunocompromised individuals and those with preexisting respiratory conditions. Prevention of infection in patients at high risk for influenza complications is especially critical given the ongoing COVID-19 pandemic. This CME program will deliver the latest data and recommendations regarding timely diagnosis and treatment of influenza so that clinicians are well-equipped to compare the efficacy and safety of available antiviral therapies for influenza prophylaxis and treatment. Using case examples, experts will discuss strategies for incorporating the most appropriate therapeutic regimen to reduce morbidity and mortality in patients who are at high risk for influenza-related complications.
Activity Chair

Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Institute for Global Health and Infectious Diseases
The University of North Carolina School of Medicine
Chapel Hill, NC
Disclosure:
Adjudication Committee: Janssen, Syneos
Faculty

Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Chicago, IL
Disclosure:
Royalty: UpToDate
Consulting Fee: AlloVir, Celltrion, Genentech/Roche, Janssen, Shionogi, Viracor Eurofins
Contracted Research: AiCuris, Genentech/Roche, Janssen, Shire

George and Esther Gross Presidential Professor
Chief, Division of Pediatric Infectious Diseases
University of Utah
Director, Hospital Epidemiology Program
Primary Children's Hospital
Salt Lake City, UT
Disclosure:
Royalty: Antimicrobial Therapy, Inc.
Consulting Fee: Genentech, Merck, Seqirus
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.75 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com